

Supplementary Table S1. Quality assessment of eligible studies (Newcastle-Ottawa Scale).

Study	Selection			Comparability			Outcome		Total
	Adequacy of case definition	Number of case	Representativeness of the cases	Ascertainment of relevant cancers	Ascertainment of genotyping method	HWE	Assessment of outcome	Adequate follow up	
Khorshidi 2017	HR	1	0	1	1	1	1	1	7
Kang M 2015		1	1	1	1	1	1	1	8
Taheri M 2017		1	0	1	1	1	1	1	7
Peng R 2017		1	1	1	1	1	1	1	8
Liu Y 2012		1	1	1	1	1	1	1	8
Li Y 2017		1	1	1	1	1	1	1	8
Gong WJ 2016		1	1	1	1	1	1	1	8
Hu P 2017		1	1	1	1	1	1	1	8
Shaker OG 2017		1	0	1	1	0	1	1	6
He BS 2017		1	1	1	1	1	1	1	8
Duan F 2017		1	1	1	1	1	1	1	8
Li L 2016		1	1	1	1	1	1	1	8
Sattarifard H 2017		1	1	1	1	0	1	1	7
Li L 2013		1	1	1	1	1	1	1	8
Chung S 2010		1	1	1	0	1	1	1	7
Salinas CA 2008		1	1	1	0	1	1	1	7
Zheng SL 2010		1	0	1	1	1	1	1	7

HWE, Hardy-Weinberg equilibrium.

Supplementary Table S2. The results of ORs and 95% CI of sensitivity analysis.

Excluding literature one by one	Mutation homozygote vs.		Heterozygote vs.		Recessive model
	Allelic model	wild-type	wild-type	Dominant model	
	OR(95%CI)	OR(95%CI)	OR(95%CI)	OR(95%CI)	OR(95%CI)
ANRIL rs1333048 A/C					
Overall	1.67(1.35-2.08)	2.40(1.60-3.59)	1.45(1.01-2.09)	1.79(1.28-2.51)	2.01(1.42-2.84)
Hamid Reza Khorshidi 2017	3.04(2.24-4.13)	7.55(0.75-14.00)	2.98(0.73-5.13)	4.18(0.52-6.92)	3.93(0.38-6.50)
Mohammad Taheri 2017	0.88(0.64-1.21)	0.80(0.44-1.48)	0.69(0.40-1.18)	0.73(0.44-1.20)	1.01(0.61-1.69)
ANRIL rs4977574 A/G					
Overall	0.76(0.64-0.97)	0.72(0.43-1.18)	0.62(0.44-0.87)	0.64(0.46-0.88)	0.91(0.57-1.46)
Hamid Reza Khorshidi 2017	0.71(0.50-1.00)	0.58(0.28-1.21)	0.61(0.37-0.99)	0.60(0.38-0.95)	0.76(0.38-1.50)
Mohammad Taheri 2017	0.82(0.58-1.15)	0.87(0.43-1.74)	0.63(0.39-1.02)	0.68(0.42-1.07)	1.08(0.56-2.09)
ANRIL rs10757278 A/G					
Overall	2.05(1.64-2.57)	4.26(2.67-6.78)	2.12(1.45-3.11)	2.57(1.80-3.69)	2.63(1.79-3.87)
Hamid Reza Khorshidi 2017	3.31(2.40-4.56)	11.20(0.51-22.91)	4.74(0.49-9.03)	6.40(0.46-11.84)	3.94(0.36-6.57)
Mohammad Taheri 2017	1.25(0.90-1.71)	1.64(0.83-3.28)	1.21(0.73-2.00)	1.30(0.80-2.10)	1.47(0.79-2.73)
ANRIL rs1333045 C/T					
Overall	1.14(0.92- 1.43)	1.29(0.83-1.99)	1.03(0.71-1.49)	1.11(0.79-1.56)	1.29(0.89-1.88)
Hamid Reza Khorshidi 2017	1.00(0.73-1.37)	0.98(0.52-1.84)	1.09(0.67-1.80)	1.06(0.66-1.69)	0.93(0.53-1.63)
Mohammad Taheri 2017	1.31(0.95-1.81)	1.67(0.90-3.08)	0.96(0.55-1.66)	1.17(0.70-1.95)	1.72(1.03-2.85)
MALAT1 rs619586 A/G					
Overall	0.77(0.65-0.91)	0.58(0.28-1.19)	0.78(0.65-0.94)	1.19(0.87-1.62)	0.61(0.30-1.26)
Yao Liu 2012	0.97(0.50-0.91)	0.65(0.25-1.72)	0.65(0.46-0.92)	0.65(0.25-1.72)	0.70(0.26-1.85)
Rui Peng 2017	0.82(0.67-1.00)	0.51(0.17-1.50)	0.84(0.67-1.04)	0.51(0.17-1.50)	0.52(0.18-1.53)
HOTTIP rs1859168 A/C					
Overall	1.31(1.19-1.45)	1.54(1.27-1.87)	1.24(1.06-1.45)	1.37(1.18-1.59)	1.49(1.26-1.76)

Wei-Jing Gong 2016	1.32(1.18-1.47)	1.54(1.24-1.90)	1.18(0.99-1.41)	1.34(1.14-1.57)	1.54(1.28-1.85)
Pinghai Hu 2017	1.14(0.99-1.32)	1.15(0.87-1.51)	0.76(0.60-0.97)	0.93(0.75-1.16)	1.53(1.21-1.93)
Fujiao Duan 2017	1.43(1.27-1.60)	1.83(1.51-2.45)	1.72(0.44-2.06)	1.77(1.50-2.10)	1.40(1.13-1.73)
HULC rs7763881 A/C					
Overall	0.90(0.82-0.99)	0.86(0.71-1.04)	0.74(0.63-0.86)	0.77(0.66-0.89)	1.02(0.87-1.20)
Mingqiang Kang 2015	0.90(0.82-1.01)	0.87(0.70-1.08)	0.75(0.63-0.89)	0.78(0.66-0.92)	1.02(0.84-1.22)
Yao Liu 2012	0.86(0.72-1.03)	0.84(0.56-1.26)	0.63(0.46-0.85)	0.66(0.50-0.89)	1.05(0.74-1.49)
PRNCR1 rs16901946 G/A					
Overall	1.15(1.06-1.24)	1.26(1.06-1.50)	1.15(1.02-1.28)	1.17(1.06-1.30)	1.21(1.03-1.43)
Bang-Shun He 2017	1.12(1.02-1.22)	1.21(1.01-1.45)	1.11(0.98-1.25)	1.13(1.01-1.27)	1.17(0.99-1.39)
Lijuan Li 2016	1.18(1.08-1.28)	1.36(1.14-1.63)	1.13(1.00-1.28)	1.18(1.06-1.33)	1.31(1.11-1.54)
Suyoun Chung 2010	1.08(0.96-1.21)	1.01(0.80-1.29)	1.18(0.99-1.39)	1.15(0.98-1.34)	1.00(0.80-1.25)
PRNCR1 rs13252298 G/A					
Overall	0.78(0.72-0.84)	0.67(0.56-0.81)	0.69(0.62-0.77)	0.81(0.73-0.90)	0.85(0.72-1.01)
Bang-Shun He 2017	0.76(0.71-0.84)	0.66(0.54-0.80)	0.67(0.59-0.76)	0.81(0.72-0.91)	0.86(0.71-1.03)
Lijuan Li 2016	0.74(0.68-0.80)	0.62(0.51-0.75)	0.63(0.56-0.71)	0.75(0.67-0.84)	0.82(0.69-0.98)
Lijuan Li 2013	0.78(0.72-0.85)	0.67(0.56-0.82)	0.69(0.61-0.78)	0.83(0.74-0.93)	0.86(0.72-1.03)
Suyoun Chung 2010	0.95(0.85-1.07)	0.96(0.74-1.26)	0.87(0.74-1.01)	0.88(0.75-1.02)	1.14(0.89-1.46)
PRNCR1 rs7007694 C/T					
Overall	1.02(0.94-1.11)	1.19(0.98-1.44)	0.96(0.86-1.07)	0.99(0.89-1.10)	1.19(0.99-1.44)
Bang-Shun He 2017	1.01(0.93-1.11)	1.17(0.95-1.44)	0.94(0.83-1.06)	0.97(0.87-1.09)	1.17(0.96-1.44)
Lijuan Li 2016	1.07(0.98-1.16)	1.27(1.03-1.54)	0.99(0.89-1.12)	1.03(0.93-1.16)	1.25(1.03-1.52)
Hedieh Sattarifard 2017	1.04(0.96-1.13)	1.18(0.98-1.45)	0.98(0.87-1.09)	1.01(0.91-1.12)	1.19(0.99-1.44)
Lijuan Li 2013	1.01(0.93-1.10)	1.14(0.92-1.40)	0.95(0.84-1.07)	0.97(0.87-1.09)	1.14(0.94-1.39)
Suyoun Chung 2010	0.97(0.85-1.10)	1.16(0.80-1.67)	0.90(0.76-1.05)	0.92(0.79-1.08)	1.19(0.83-1.71)
PRNCR1 rs1016343 C/T					

Overall	1.31(1.22-1.41)	1.66(1.41-1.97)	1.35(1.22-1.49)	1.41(1.28-1.55)	1.42(1.21-1.66)
Lijuan Li 2016	1.36(1.27-1.47)	1.86(1.55-2.22)	1.37(1.28-1.52)	1.45(1.31-1.59)	1.58(1.33-1.88)
Lijuan Li 2013	1.38(1.28-1.49)	1.88(1.57-2.26)	1.38(1.25-1.54)	1.46(1.32-1.61)	1.59(1.33-1.89)
Claudia A. Salinas 2008	1.30(1.19-1.41)	1.60(1.33-1.94)	1.36(1.21-1.54)	1.42(1.26-1.59)	1.35(1.13-1.61)
Siqun Lilly Zheng 2010	1.29(1.20-1.39)	1.61(1.35-1.91)	1.32(1.19-1.46)	1.37(1.25-1.51)	1.40(1.19-1.65)
Suyoun Chung 2010	1.20(1.09-1.32)	1.31(1.05-1.63)	1.30(1.14-1.48)	1.31(1.16-1.48)	1.13(0.92-1.39)
PRNCR1 rs1456315 A/G					
Overall	0.77(0.72-0.83)	0.59(0.50-0.69)	0.76(0.68-0.83)	0.72(0.66-0.79)	0.70(0.60-0.81)
Lijuan Li 2016	0.77(0.72-0.83)	0.60(0.51-0.71)	0.74(0.67-0.82)	0.71(0.65-0.78)	0.72(0.62-0.84)
Lijuan Li 2013	0.75(0.70-0.81)	0.54(0.46-0.64)	0.75(0.68-0.83)	0.71(0.64-0.78)	0.66(0.56-0.76)
Suyoun Chung 2010	0.93(0.85-1.02)	0.74(0.60-0.91)	0.99(0.87-1.13)	0.96(0.84-1.08)	0.80(0.67-0.97)
Claudia A. Salinas 2008	0.72(0.66-0.79)	0.48(0.39-0.60)	0.71(0.63-0.80)	0.68(0.61-0.76)	0.60(0.49-0.75)

The results are in bold if the ORs and 95% CIs ranged from insignificantly to statistically significantly after removal of an individual study.